References
- Zubrod C G. Chemical control of cancer. Proc Natl Acad Sci (USA) 1972; 69: 1042–1047
- Klohs W D, Steinkampf R W. Possible link between the intrinsic drug resistance of colon tumors and a detoxification mechanism of intestinal cells. Cancer Res 1988; 48: 3025–3030
- Goldie J H, Coldman A J. Quantitative model for multiple levels of drug resistance in clinical tumors. Cancer Treat Rep 1983; 67: 923–931
- Capps D, Kesten S R, Shillis J, et al. 2-Aminoalkyl-5-nitropyrazolo [3,4,5-kl]acridines, a new class of anticancer agents. Proc Am Assoc Cancer Res 1986; 27: 277
- Radzikowski C, Ledochowski A, Hrabowska M, et al. A search for antitumor compounds. VI. Biologic studies. Antitumor properties of 29 new acridine derivatives of groups XVII-XVIII. Arch Immunol Ther Exp 1969; 17: 99–110
- Werbel L M, Elslager E F, Fry D W, . 5-Aminoanthrapyrazoles (CI-937, CI-941, CI-942): A novel class of DNA binders with broad-spectrum anticancer activity. New Avenues in Developmental Cancer Chemotherapy, K R Harrap, T A Connors, et al. Academic Press, Orlando 1987; 355–365
- Sebolt J S, Scavone S V, Pinter C D, et al. Pyrazoloacridines, a new class of anticancer agents with selectivity against solid tumors in vitro. Cancer Res 1987; 47: 4299–4304
- Crooke S T, Duvenny V H, Galvan L, et al. Structure-activity relations of anthracyclines relative to effects on macromolecular synthesis. Mol Pharmacol 1977; 14: 290–298
- Tanabe M, Miyamoto T. Effect of aclacinomycin-A on survival and progression of mouse L cells through the cell cycle. Gann 1983; 74: 699–707
- Sebolt J S, Leopold W R, Hamelehle K L, et al. Solid tumor selectivity of the 2-aminoalkyl-5-nitropyrazolo[3,4,5-kl]acridines, a novel class of DNA-binding antitumor agents. Proc Am Assoc Cancer Res 1986; 27: 421
- Jackson R C, Leopold W R, Sebolt J S. Biochemical and experimental chemotherapy studies of the pyrazoloacridines. Proc Am Assoc Cancer Res 1988; 29: 536–538
- Corbett T H, Polin L, Wozniak A J, et al. The use of a multiple tumor soft agar disk diffusion assay to detect agents with selective solid tumor activity. Proc Am Assoc Cancer Res 1988; 29: 533–534
- Paull K D, Hodes L, Shoemaker R H, et al. The “mean graph”—a graphic pattern display format to depict differential growth inhibition, and “compare” a pattern recognition system which can identify structurally similar or mechanistically similar test agents from in vitro screening data. Proc Am Assoc Cancer Res 1988; 29: 488
- Scavone S V, Sebolt J S, Pinter C D, et al. Biological and biochemical properties of the 2-aminoalkyl-5-nitropyrazolo[3,4,5-kl]acridines (pyrazoloacridines). Proc Am Assoc Cancer Res 1986; 27: 277
- Sebolt J S, Havlick M J, Hamelehle K L, et al. Activity of the pyrazoloacridines against multidrug resistant tumor cells. Cancer Chemother Pharmacol 1989; 24: 219–224
- Havlick M J, Sebolt J S, Leopold W R, et al. Characterization and drug sensitivity of an Adriamycin-resistant subline of B16/BL6 murine melanoma in vitro and in vivo. J Cell Biol 1985; 101: 482a
- Klohs W D, Steinkampf R W, Havlick M J, et al. Resistance to anthrapyrazoles and anthracyclines in multidrug-resistant P388 murine leukemia cells: reversal by calcium blockers and calmodulin antagonists. Cancer Res 1986; 46: 4352–4356
- Goldin A, Venditti J M, MacDonald J S, et al. Current results of the screening program at the Division of Cancer Treatment, National Cancer Institute. Eur J Cancer 1981; 17: 129–142
- Corbett T H, Valeriote F A, Baker L H. Is the P388 murine tumor no longer adequate as a drug discovery model?. Invest New Drugs 1987; 5: 3–20
- Schabel F M, Griswold D P, Corbett T H, . Variable responses of advanced solid tumors of mice to treatment with anticancer drugs. Design of Models for Testing Cancer Therapeutic Agents, I J Fidler, R J White, et al. Van Nostrand Reinhold Co., New York 1982; 95–113